Health
STAT+: Beyond statins, one drug lowered heart attack risk by 20%
Publication: STAT
Author: Elizabeth Cooney
Source published: 05/11/2026, 14:00:00 UTC
Briefing created: 22/11/2026, 21:27:31 UTC
Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 06/11/2026, 08:21:26 UTC.
Briefings
A real-world evidence trial compared evolocumab (Repatha) and ezetimibe (Zetia) for lowering LDL cholesterol. Evolocumab was the only drug to significantly reduce heart attack risk, lowering it by 20% compared to ezetimibe. The study used real-world data from patients treated with these medications, though specific patient counts and long-term follow-up details are not fully detailed in the provided text.
Key points
- Evolocumab (Repatha) significantly reduced heart attack risk by 20% compared to ezetimibe (Zetia) in a real-world evidence trial.
- The trial compared two cholesterol-lowering drugs: the injectable evolocumab and the oral ezetimibe.
Context
Cardiologists often choose between statins and other cholesterol-lowering drugs. This study compared evolocumab and ezetimibe, with evolocumab winning the trial. The finding matters because it identifies a specific drug that may offer greater heart protection than alternatives.
Limitations
The evidence is based on real-world data from a single trial, which may not represent all patient populations. Specific patient counts, long-term follow-up details, and exact numbers of heart attacks prevented are not fully detailed in the provided text.
Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 22/11/2026, 21:27:31 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.
View archived briefing on IPFS
bafybeig4mecc2flajldkm6xb6mmus4t3azzukse7zidapij7nfoed5q6my